Cancer in pregnancy: Incidence, clinical handling, and consequences for mother and child in a Danish cohort study

​Cancer in pregnancy (CIP) is rare with an incidence around one per 1000 pregnant women. CIP has a high level of complexity as the treatment and staging of the pregnant woman must take the potential harmful exposure of the fetus into account. 

A research project by Doctor and PhD-student Iben Katinka Greiber

The survival after CIP may be influenced by various factors, including delays in diagnosis and treatment, suboptimal treatment. The handling of these patients is difficult due to mottled symptoms and an overlap in physical signs of pregnancy and cancer. 

With a retrospective study period of 40 years, we can follow mothers into old age and offspring well into adulthood, to determine overall survival, disease free survival, signs of diagnostic and/or treatment delay and non-optimal treatment; as well as the risks of short- and long-term adverse health outcomes in the offspring exposed to cancer and cancer treatment in utero.

The overall purposes of the project are to clarify the incidence of CIP in Danish women and evaluate if these patients may have suffered from diagnostic and/or treatment delay as well as worse survival compared to non-pregnant women with the same cancer type. We also aim to examine, if CIP have a negative effect on the developing fetus, and if the cancer treatment is harmful or safe for the fetus, when administered during the pregnancy. 

Responsible editor